🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Incredibly excited to publish our NOTIFY-LVH randomized trial of 648 patients within the Mass General Brigham system, highlighting the potential of leveraging preexisting cardiovascular data to improve the detection and treatment of chronic cardiovascular conditions.

Lucky to work with you!

Thank you so much American College of Cardiology ! This is all due to all my amazing mentors 🙏and colleagues! ❤️I am excited for all the work ahead! Marcelo Di Carli Ron Blankstein Kat Liao Joseph Merola, MD MMSc Monica Mukherjee MD, MPH OMRF Penn IGG #JoelKatz Brigham and Women’s Cardiovascular Imaging Program AntonioAbbate Dr. Michael Garshick

Simultaneous publications from #FINEARTSHF w #ACC2025 in JACC Journals & JAMA Cardiology 🔥 Reduction in New-Onset AF across CKM Spectrum 🔥 Effects on Mode of Death 🔥 Consistent Benefits across Functional Class, Kidney Risk & AF Subgroups Find out more 👇🏾 finearts-hf.org

So proud of you Safia Chatur, MD !!!

Our latest on 🫀 health, 🧬, & 🤰 now out in JACC Journals #JACC ⬆️ 1st-trimester CV health strongly associates w/ ⬇️ risk of hypertensive disorders of 🤰 (HDP) overall & across levels of HDP 🧬 risk ➡️ opp to prevent 🤰 complications & long-term CVD jacc.org/doi/10.1016/j.…

🤰Pregnancy complications aren’t just chance! Your genetic risk + first-trimester CV health could predict hypertensive disorders in pregnancy. New study = key implications for maternal health! 💡🔬 jacc.org/doi/10.1016/j.… #JACC #Hypertension #CardioObstetrics #CardioOB

Women have been honored with 10 out of the 21 Distinguished Awards at #ACC25. Let’s take a moment to celebrate the accomplishments of these brilliant cardiologists - congratulations to you all! 🧵⬇️ #CardioTwitter #WIC

Does the CV benefit of evolocumab differ in patients with autoimmune or inflammatory diseases? The answer lies at the intersection of dyslipidemia and inflammation. A 🧵 on our new Circulation paper. (1/10) Link: ahajournals.org/doi/abs/10.116… TIMI Study Group Robert Giugliano

Michael Honigberg, M.D., M.P.P., FAHA, MassGeneral News, Harvard Medical School in collaboration with teams from Salem State, Brigham and Women's Hospital & UPMC, is part of a new $15 million initiative to study CKM syndrome in women. spr.ly/60182XJrj 📸: copyright Massachusetts General Hospital

Finerenone Reduces New-Onset Atrial Fibrillation in FINE-HEART By Maria A. Pabón, MD Muthu Vaduganathan et al. jacc.org/doi/10.1016/j.…

Huge congrats to Maria A. Pabón, MD for winning the inaugural Mass General Heart MGH Corrigan Women's Heart Health Program / Inova Schar Heart and Vascular Women's Heart Health Young Investigator Award (basic/translational science category) for her work on endothelial cell transcriptomics in preeclampsia (ahajournals.org/doi/10.1161/CI…)!

Grateful to have been part of it. Can’t wait for next year’s event!

New results from #FINEARTSHF in European Society of Cardiology Journals #EJHF, in time for #HeartFailure2025 Finerenone reduced HF events and CV death in HFmrEF/HFpEF consistently, regardless of baseline NT-proBNP And reduced NT-proBNP 12% vs placebo at 3 & 12 months onlinelibrary.wiley.com/doi/epdf/10.10…

I am happy to have our work presented on the differences in Obstetric and Cardiac Outcomes of Pregnant congenital heart disease (CHD) by Rurality at #ACOG2025 with the help of Mehr Jain, Maria A. Pabón, MD, Camilo Jaimes, Dr. Sparagna, and Dr. Dahan! We would not be able to complete

Finerenone in Heart Failure With Improved Ejection Fraction FINEARTS-HF Randomized Clinical Trial Patients with HFimpEF remain at heightened risk of adverse outcomes, but finerenone safely and effectively mitigated this risk in this high-risk population jamanetwork.com/journals/jamac…

FINEARTS-HF is the 2nd large RCT to include patients with #HFimpEF. Out now🚨 our new JAMA Cardiology analysis shows that finerenone confers benefit in this group, despite their persistent risk of adverse outcomes jamanetwork.com/journals/jamac… Muthu Vaduganathan scottdavidsolomon orlyvardeny

Patients with heart failure and HFimpEF remain at high risk for cardiovascular events, but finerenone consistently reduces this risk without significant adverse effects. ja.ma/4jjmY0T orlyvardeny Muthu Vaduganathan Sanjiv J. Shah, MD Adriaan Voors clara saldarriaga

Finerenone in Heart Failure with Improved Ejection Fraction in #FINEARTSHF led by Maria A. Pabón, MD in JAMA Cardiology jamanetwork.com/journals/jamac…

⏳This marks the end of six life changing weeks Brigham and Women's Hospital #Boston ♥️I am full of gratitude for the opportunity to work with the amazing scottdavidsolomon Muthu Vaduganathan Safia Chatur, MD Maria A. Pabón, MD Jon Cunningham 💸 Thank you British Cardiovascular Society Heart Research UK for this opportunity